Itvisma (onasemnogene abeparvovec-brve)
An approved treatment for Spinal Muscular Atrophy.
The same compound appears under different names depending on the context. Here is how to identify Onasemnogene abeparvovec-brve wherever you encounter it, plus the key facts at a glance.
- Generic name
- Onasemnogene abeparvovec-brve
- Brand name
- Itvisma
- Development codes
- OAV101 IT, AVXS-101 IT
- Drug class
- Gene therapy (intrathecal)
- Manufacturer
- Novartis Gene Therapies
- How it's taken
- Given as a single one-time intrathecal injection (lumbar puncture) at a specialized treatment center.
An intrathecal gene replacement therapy for spinal muscular atrophy (SMA) approved for patients 2 years and older with a confirmed SMN1 gene mutation. Itvisma is the same AAV9 vector platform as Zolgensma but delivered directly into the spinal fluid rather than the bloodstream, making it the first gene replacement therapy available to older children, teens, and adults with SMA.
Where Onasemnogene abeparvovec-brve fits
First and only gene replacement therapy approved for SMA patients 2 years and older. Fills the major gap left by Zolgensma, which is generally restricted to younger children and weight-based dosing. For older patients previously limited to chronic therapies (nusinersen or risdiplam), Itvisma offers a one-time treatment option.
How Onasemnogene abeparvovec-brve works
Itvisma uses a harmless adeno-associated virus 9 (AAV9) vector to deliver a working copy of the SMN1 gene directly to motor neurons in the spinal cord. In SMA, the SMN1 gene is missing or non-functional, so motor neurons gradually die.
By delivering the replacement gene intrathecally (directly into the spinal fluid), Itvisma concentrates the therapy where it is needed most. The single dose is fixed and does not need to be adjusted for age or body weight, which is what makes treatment feasible in older, larger patients.
Mechanism: AAV9-based gene replacement therapy delivered intrathecally (directly into the spinal fluid) that provides a functional copy of the SMN1 gene to motor neurons
Side effects and safety
The most common side effects in trials were upper respiratory infections, upper stomach symptoms such as vomiting, fever, and headache. The label also warns about nerve damage causing numbness, tingling or pain in the hands and feet (starting about 3 weeks after treatment), thrombotic microangiopathy (a dangerous clotting problem), and raised troponin (a heart marker). Itvisma has a boxed warning (the FDA's strongest warning) for serious liver injury, so liver function is checked before treatment and for at least 3 months after, and corticosteroids are given before and after the injection. It can also lower platelet counts (thrombocytopenia), so platelets are checked before treatment and at least weekly for the first month. The label also notes a theoretical risk of tumors from the gene therapy. Patients should be tested for anti-AAV9 antibodies before treatment.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Onasemnogene abeparvovec-brve
Given as a single one-time intrathecal injection (lumbar puncture) at a specialized treatment center. Patients receive corticosteroids before and after the procedure to manage immune response. Unlike weight-based IV Zolgensma, Itvisma uses a fixed dose, allowing it to be given to older children, teens, and adults regardless of size.
Availability and cost
Only available as the brand-name product.
One-time AAV9 intrathecal gene therapy. Pricing reflects the same complex viral vector manufacturing as Zolgensma plus the surgical/intrathecal administration overhead, in a curative-intent single-dose model.
Help paying for Itvisma
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Insurance and case manager help
A dedicated Case Coordinator helps with benefits verification, prior authorization, appeals, financial support options, and tracking treatment delivery.
The official page does not say who qualifies. Ask the program. · source - Copay help
ZOLGENSMA and ITVISMA CopayAssist Program helps reduce out-of-pocket costs for eligible patients with private insurance.
For: private insurance · source - Free medicine program
The Novartis Patient Assistance Program for ITVISMA is available for eligible people with SMA and families; contact Novartis Patient Support.
The official page does not say who qualifies. Ask the program. · source
Good to know: Enrollment requires a signed Novartis Patient Support Start Form. Eligibility rules for the patient assistance program and copay limits are not stated on the official page.
- From a charity · TotalAssist (formerly PAN Foundation)Spinal Muscular Atrophy fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $6,500 per year. Requires health insurance (any kind).
- From a charity · Cure SMAEquipment Pool and Travel Support Package fundApply directly
Pays for: Medical equipment loans (wheelchairs, car beds) and travel equipment.
The foundation says: “Status not shown on page” - From a charity · Muscular Dystrophy AssociationMDA Durable Medical Equipment (DME) Grant Program fundApply directly
Pays for: Medical equipment (wheelchairs, lifts, canes and other DME), up to $1,000 per year.
The foundation says: “Status not shown on page”
Access and eligibility
Indicated for adults and children 2 years and older with SMA and a confirmed mutation in the SMN1 gene. Patients who were previously treated with Zolgensma should not receive Itvisma. Anti-AAV9 antibodies are tested before treatment, and the clinical trials only enrolled patients with low antibody levels (1:50 or below).
Source: Novartis (Itvisma approval announcement)
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
FDA approval (November 24, 2025) was based on the Phase 3 STEER study and supportive findings from the ongoing Phase 3b STRENGTH study. STEER showed a statistically significant improvement in the Hammersmith Functional Motor Scale Expanded (HFMSE): scores rose 2.39 points with Itvisma and 0.51 points with a sham procedure, a difference of 1.88 points, in treatment-naive SMA patients 2-17 years old.
Development history
Developed by Novartis Gene Therapies as the intrathecal counterpart to Zolgensma. Although both products use the same AAV9 vector and the same transgene, FDA approval was sought separately for the intrathecal route given the different administration method, dosing, and patient population. Approved November 24, 2025 as the first gene replacement therapy available for SMA patients age 2 and older, including teens and adults.
Explore Spinal Muscular Atrophy trials
Other Spinal Muscular Atrophy treatments
Common questions about Onasemnogene abeparvovec-brve
▸What is Onasemnogene abeparvovec-brve (Itvisma)?
An intrathecal gene replacement therapy for spinal muscular atrophy (SMA) approved for patients 2 years and older with a confirmed SMN1 gene mutation. Itvisma is the same AAV9 vector platform as Zolgensma but delivered directly into the spinal fluid rather than the bloodstream, making it the first gene replacement therapy available to older children, teens, and adults with SMA.
▸How does Onasemnogene abeparvovec-brve work?
Itvisma uses a harmless adeno-associated virus 9 (AAV9) vector to deliver a working copy of the SMN1 gene directly to motor neurons in the spinal cord. In SMA, the SMN1 gene is missing or non-functional, so motor neurons gradually die.
By delivering the replacement gene intrathecally (directly into the spinal fluid), Itvisma concentrates the therapy where it is needed most. The single dose is fixed and does not need to be adjusted for age or body weight, which is what makes treatment feasible in older, larger patients.
▸What are the side effects of Onasemnogene abeparvovec-brve?
The most common side effects in trials were upper respiratory infections, upper stomach symptoms such as vomiting, fever, and headache. The label also warns about nerve damage causing numbness, tingling or pain in the hands and feet (starting about 3 weeks after treatment), thrombotic microangiopathy (a dangerous clotting problem), and raised troponin (a heart marker). Itvisma has a boxed warning (the FDA's strongest warning) for serious liver injury, so liver function is checked before treatment and for at least 3 months after, and corticosteroids are given before and after the injection. It can also lower platelet counts (thrombocytopenia), so platelets are checked before treatment and at least weekly for the first month. The label also notes a theoretical risk of tumors from the gene therapy. Patients should be tested for anti-AAV9 antibodies before treatment.
▸How is Onasemnogene abeparvovec-brve taken?
Given as a single one-time intrathecal injection (lumbar puncture) at a specialized treatment center. Patients receive corticosteroids before and after the procedure to manage immune response. Unlike weight-based IV Zolgensma, Itvisma uses a fixed dose, allowing it to be given to older children, teens, and adults regardless of size.
▸Is Onasemnogene abeparvovec-brve FDA approved?
Yes, Onasemnogene abeparvovec-brve (Itvisma) is FDA approved (2025) for the treatment of Spinal Muscular Atrophy.
▸How does intrathecal Zolgensma differ from the IV version?
The intrathecal version delivers the gene therapy directly into the spinal fluid, allowing treatment of older patients (age 2 and above) whose blood-brain barrier may limit IV gene delivery. The IV version is for children under 2 years old.
▸Who is eligible for intrathecal Zolgensma?
Intrathecal onasemnogene-abeparvovec-brve is approved for SMA patients aged 2 years and older. It fills the age gap for patients too old for IV Zolgensma, providing a gene therapy option across the lifespan.
▸When was this version approved?
The intrathecal formulation was approved in 2025, expanding the gene therapy option beyond the under-2 age group covered by the original IV Zolgensma approved in 2019.
▸Is this also a one-time treatment?
Yes. Like the IV version, intrathecal Zolgensma is a one-time treatment aimed at providing sustained SMN protein production. The intrathecal delivery targets the central nervous system directly.
▸What monitoring is required after treatment?
Similar to IV Zolgensma, liver function monitoring, corticosteroid management, and regular follow-up are required after intrathecal administration. Specific monitoring protocols may differ based on the delivery route.